ストックスクリーナーアプリを入手
3.35
6.01%
0.19
前日終値:
$3.16
開ける：
$3.28
24時間の取引高:
11.28M
Relative Volume:
3.49
時価総額：
$365.80M
収益：
-
当期純損益:
$-209.38M
株価収益率:
-1.785
EPS:
-1.8768
ネットキャッシュフロー:
$-179.81M
1週間 パフォーマンス:
+25.94%
1か月 パフォーマンス:
+9.12%
6か月 パフォーマンス:
+3.72%
1年 パフォーマンス:
+18.37%
1日の値動き範囲:
$3.19
$3.38
1週間の範囲:
$2.66
$3.38
52週間の値動き範囲:
$2.40
$5.45
Rocket Pharmaceuticals Inc Stock (RCKT) Company Profile
名前
Rocket Pharmaceuticals Inc
セクター
電話
646-440-9100
住所
350 FIFTH AVENUE, NEW YORK, NY
Compare RCKT vs VRTX, REGN, ARGX, ALNY, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
RCKT
Rocket Pharmaceuticals Inc
|
3.35 | 365.80M | 0 | -209.38M | -179.81M | -1.8768 |
VRTX
Vertex Pharmaceuticals Inc
|
451.63 | 114.63B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
609.94 | 63.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.72 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.09 | 37.13B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
162.99 | 34.65B | 742.00K | -1.37B | -1.07B | -7.0731 |
Rocket Pharmaceuticals Inc Stock (RCKT) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-11-18 | ダウングレード | JP Morgan | Neutral → Underweight |
| 2025-08-20 | アップグレード | BofA Securities | Neutral → Buy |
| 2025-07-25 | ダウングレード | BofA Securities | Buy → Neutral |
| 2025-05-30 | ダウングレード | Evercore ISI | Outperform → In-line |
| 2025-05-28 | ダウングレード | Goldman | Neutral → Sell |
| 2025-05-28 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2025-05-28 | ダウングレード | Jefferies | Buy → Hold |
| 2025-05-28 | ダウングレード | Leerink Partners | Outperform → Market Perform |
| 2025-05-28 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2025-05-27 | ダウングレード | Needham | Buy → Hold |
| 2025-05-27 | ダウングレード | TD Cowen | Buy → Hold |
| 2025-03-12 | 開始されました | BMO Capital Markets | Outperform |
| 2024-12-30 | 開始されました | Wedbush | Outperform |
| 2024-12-18 | 開始されました | Jefferies | Buy |
| 2024-10-16 | 開始されました | Scotiabank | Sector Outperform |
| 2024-04-02 | 開始されました | Goldman | Neutral |
| 2023-10-24 | 開始されました | Cantor Fitzgerald | Overweight |
| 2023-02-01 | 開始されました | Morgan Stanley | Overweight |
| 2022-11-08 | 開始されました | Canaccord Genuity | Buy |
| 2022-11-01 | 開始されました | BTIG Research | Buy |
| 2022-07-08 | 開始されました | Raymond James | Outperform |
| 2021-10-20 | 再開されました | Cowen | Outperform |
| 2021-03-02 | 開始されました | Stifel | Buy |
| 2021-02-18 | 開始されました | Needham | Buy |
| 2020-12-16 | 開始されました | UBS | Buy |
| 2020-12-08 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2020-07-02 | 開始されました | JP Morgan | Overweight |
| 2020-06-25 | 再開されました | BofA/Merrill | Buy |
| 2020-06-01 | 再開されました | Oppenheimer | Outperform |
| 2019-11-06 | 開始されました | Chardan Capital Markets | Buy |
| 2019-09-26 | 開始されました | Piper Jaffray | Overweight |
| 2019-04-23 | 開始されました | Robert W. Baird | Outperform |
| 2019-03-15 | 開始されました | BofA/Merrill | Buy |
| 2019-02-05 | 開始されました | Oppenheimer | Outperform |
| 2018-09-13 | 開始されました | Ladenburg Thalmann | Buy |
| 2018-07-10 | 開始されました | William Blair | Outperform |
すべてを表示
Rocket Pharmaceuticals Inc (RCKT) 最新ニュース
Rocket Pharma updates cash position after selling priority review voucher - MSN
Rocket Pharmaceuticals Inc (RCKT) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Rocket Pharmaceuticals Inc (RCKTW) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Rocket Pharmaceuticals Inc (RCKTW) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Rocket Pharmaceuticals Inc (RCKT) Valuation: PE, PB & Fair Value Analysis - TradingKey
Rocket Pharmaceuticals Inc (RCKT) Institutional Confidence - TradingKey
Rocket Pharmaceuticals Inc (RCKT) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Rocket Pharmaceuticals Inc (RCKT) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Rocket Pharmaceuticals Inc (RCKT) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Rocket Pharmaceuticals Inc (RCKTW) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Rocket Pharmaceuticals Inc (RCKT) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Rocket Pharmaceuticals Inc (RCKTW) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Rocket Pharmaceuticals Inc - TradingKey
Rocket Pharmaceuticals Inc (RCKT) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Rocket Pharmaceuticals Inc (RCKTW) Valuation: PE, PB & Fair Value Analysis - TradingKey
Rocket Pharmaceuticals Inc (RCKTW) Institutional Confidence - TradingKey
Rocket Pharmaceuticals Inc (RCKTW) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Rocket Pharma Reaps $180M From Sale of FDA Drug Review Fast Pass - MedCity News
Rocket Pharma closes sale of PRV for $180 million - The Pharma Letter
RCKT Stock Jumps Over 10% Premarket: FDA Approves Its First Gene Therapy For Rare Childhood Immune Disease - Stocktwits
Rocket Pharmaceuticals (RCKT) Secures Over $320M Following PRV S - GuruFocus
Rocket Pharmaceuticals (RCKT) Secures $180M from Rare Disease Vo - GuruFocus
Rocket Pharmaceuticals Closes $180 Million Priority Review Voucher Sale - grafa.com
Rocket Pharmaceuticals sells priority review voucher for $180M - Investing.com
Rocket Pharmaceuticals sells priority review voucher for $180M By Investing.com - Investing.com Australia
Bank of America Securities Reaffirms Their Buy Rating on Rocket Pharmaceuticals (RCKT) - The Globe and Mail
Rocket Pharmaceuticals (NASDAQ: RCKT) sells priority review voucher for $180M, extends runway - Stock Titan
Rocket Pharmaceuticals Announces Closing Of Sale Of Rare Pediatric Disease Priority Review Voucher For $180 Million - TradingView
Rocket Pharmaceuticals Announces Closing of Sale of Rare Pediatric Disease Priority Review Voucher for $180 Million - The Joplin Globe
Rocket Pharmaceuticals completes $180 million priority review voucher sale - StreetInsider
symbol__ Stock Quote Price and Forecast - CNN
RCKT Technical Analysis & Stock Price Forecast - Intellectia AI
BofA Securities Maintains Rocket Pharmaceuticals(RCKT.US) With Buy Rating, Maintains Target Price $10 - Moomoo
RCKT: Cardiac gene therapy pipeline advances with pivotal trials and strong financial runway - TradingView
Rocket Pharmaceuticals Inc at Goldman Sachs Healthcare Conference Transcript - GuruFocus
Rocket Pharmaceuticals (RCKT) Holds Steady at $2.92: Consolidation Before a Potential Move?Covered Call Trade - newsline.com
Rocket Pharmaceuticals, Inc. Stock 12‑Month Price Target Raised to $9.39, Implies 225% Upside - TradingView
BofA Securities Maintains Rocket Pharmaceuticals(RCKT.US) With Buy Rating, Raises Target Price to $10 - Moomoo
Did You Lose Money on Rocket Pharmaceuticals, Inc. (RCKT)? Levi & Korsinsky Urges Investors to Act Before August 11, 2025 - TMX Newsfile
Investors in Rocket Pharmaceuticals, Inc. (RCKT): Protect Your RightsContact Levi & Korsinsky Before August 11, 2025 - TMX Newsfile
RCKT Stock Chart | ROCKET PHARMACEUTICALS INC (NASDAQ:RCKT) - ChartMill
Rocket Pharmaceuticals (NASDAQ: RCKT) exchanges options; 686,137 new grants - Stock Titan
Rocket Pharmaceuticals (RCKT) executive swaps underwater options for new $3.00 grants - Stock Titan
From biotech to orbit: Rocket One's AI and space rebrand sends shares flying - Yahoo Finance
Rocket Pharmaceuticals to Participate in Upcoming Investor Conferences - The Joplin Globe
Rocket One Rebrand Marks Strategic Shift Toward Space AI Chip and Orbital Computing Markets (RKTO) - Yahoo Finance
Rocket Pharmaceuticals CEO Shah sells $171,840 in stock By Investing.com - Investing.com UK
Rocket Pharmaceuticals CEO Shah sells $171,840 in stock - Investing.com
[Form 4] ROCKET PHARMACEUTICALS, INC. Insider Trading Activity - Stock Titan
Rocket Pharmaceuticals (RCKT) Posts Modest Gains as Stock Tests Key Support LevelsHigh Low Breadth - thelegaladvocate.com
JP Morgan Downgrades Rocket Pharmaceuticals (RCKT) - MSN
Rocket Pharmaceuticals Inc (RCKT) 財務データ
収益
当期純利益
現金流量
EPS
0.74%
1.44%
大文字化:
|
ボリューム (24 時間):